The downgrade from Overweight to Neutral by Piper Sandler's analyst Christopher Raymond indicates a less optimistic outlook for VectivBio Holding. The lowered price target from $25 to $17 suggests a reduced potential upside for the stock, which may negatively impact its short-term price.